eli lilly's tirzepatide is the leader in weight loss sector Lilly Launches Self-Pay Vials of for Patients With Obesity The CEO of Eli Lilly

In a Phase III trial targeting people with obesity but not diabetes, Novo aimed for 25% weight loss a goal it missed in December

Finally, our findings offer a more comprehensive assessment compared with another analysis that produced indirect estimates between tirzepatide and semaglutide 2.0 mg using data solely from two RCTs [57]

Final Thoughts GLP-1 medications have transformed how we treat obesity: Semaglutide broke ground with ~15% average weight loss

Heres how to decide: If you're just starting your weight loss journey or managing Type 2 diabetes, Semaglutide is a powerful and proven option

We'll explore its specific uses and how it differs from dual-agonist therapies

Switching from semaglutide to tirzepatide: the dosing protocol Switching is increasingly common